DDInter842 DDInter336
Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States.
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fludarabine
Fludarabine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is palliated by {v} (Compound) Celecoxib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Sibutramine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Celecoxib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fludarabine
Fludarabine {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Celecoxib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cytarabine
Cytarabine {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Celecoxib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Topotecan
Topotecan {u} (Compound) downregulates {v} (Gene) ZMIZ1
ZMIZ1 {u} (Gene) is downregulated by {v} (Compound) Celecoxib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bleomycin
Bleomycin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is palliated by {v} (Compound) Celecoxib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Floxuridine
Floxuridine {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Celecoxib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bleomycin
Bleomycin {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Celecoxib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tioguanine
Tioguanine {u} (Compound) binds {v} (Gene) ABCC4
ABCC4 {u} (Gene) is bound by {v} (Compound) Celecoxib
Grepafloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Celecoxib
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine and Fludarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is palliated by Celecoxib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Celecoxib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Fludarabine and Fludarabine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Celecoxib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Cytarabine and Cytarabine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Celecoxib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Topotecan and Topotecan (Compound) downregulates ZMIZ1 (Gene) and ZMIZ1 (Gene) is downregulated by Celecoxib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Bleomycin and Bleomycin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is palliated by Celecoxib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Floxuridine and Floxuridine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Celecoxib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Bleomycin and Bleomycin (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Celecoxib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Tioguanine and Tioguanine (Compound) binds ABCC4 (Gene) and ABCC4 (Gene) is bound by Celecoxib (Compound)
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Vinorelbine and Vinorelbine (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Celecoxib (Compound)